Progress in Breast Cancer: Overview : Research in Breast Cancer: Frontiers in Genomics, Biology, and Clinical InvestigationARTEAGA, Carlos L.Clinical cancer research (Print). 2013, Vol 19, Num 23, pp 6353-6359, issn 1078-0432, 7 p.Article

Foundations of molecular therapies in breast carcinomaARTEAGA, Carlos L.Journal of mammary gland biology and neoplasia. 1999, Vol 4, Num 4, issn 1083-3021, 91 p.Serial Issue

Erlotinib (Tarceva): Potent HER1/Epidermal growth factor receptor inhibitionARTEAGA, Carlos L.Seminars in oncology. 2003, Vol 30, Num 3, issn 0093-7754, 54 p., SUP7Serial Issue

Epidermal Growth Factor Receptor-Targeted Approaches for Anticancer Therapy: Focus on ZD1839ARTEAGA, Carlos L.Drugs (Basel). 2000, Vol 60, issn 0012-6667, 46 p., SUP1Serial Issue

Impact of Genomics on Personalized Cancer MedicineARTEAGA, Carlos L; BASELGA, José.Clinical cancer research (Print). 2012, Vol 18, Num 3, pp 612-618, issn 1078-0432, 7 p.Article

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agentsCIARDIELLO, Fortunato.Drugs (Basel). 2000, Vol 60, pp 25-32, issn 0012-6667, SUP1Article

Targeting HERI/EGFR: A molecular approach to cancer therapyARTEAGA, Carlos.Seminars in oncology. 2003, Vol 30, Num 3, pp 3-14, issn 0093-7754, 12 p., SUP7Article

The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGFβDUMONT, Nancy; ARTEAGA, Carlos L.Differentiation (London). 2002, Vol 70, Num 9-10, pp 574-582, issn 0301-4681, 9 p.Article

New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs AvailableABRAMSON, Vandana; ARTEAGA, Carlos L.Clinical cancer research (Print). 2011, Vol 17, Num 5, pp 952-958, issn 1078-0432, 7 p.Article

Critical update and emerging trends in epidermal growth factor receptor targeting in cancerBASELGA, José; ARTEAGA, Carlos L.Journal of clinical oncology. 2005, Vol 23, Num 11, pp 2445-2459, issn 0732-183X, 15 p.Article

Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: Implications for drug development and practicesARTEAGA, Carlos L; BASELGA, Jose.Clinical cancer research. 2003, Vol 9, Num 5, pp 1579-1589, issn 1078-0432, 11 p.Article

Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer PatientGLÜCK, Stefan; ARTEAGA, Carlos L; OSBORNE, C. Kent et al.Clinical cancer research (Print). 2011, Vol 17, Num 17, pp 5559-5561, issn 1078-0432, 3 p.Article

Challenges and opportunities for erlotinib (Tarceva): What does the future hold?HORTOBAGYI, Gabriel N; SAUTER, Guido.Seminars in oncology. 2003, Vol 30, Num 3, pp 47-53, issn 0093-7754, 7 p., SUP7Article

Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva)HIDALGO, Manuel; BLOEDOW, Duane.Seminars in oncology. 2003, Vol 30, Num 3, pp 25-33, issn 0093-7754, 9 p., SUP7Article

Erlotinib (Tarceva): An update on the clinical trial programHERBST, Roy S.Seminars in oncology. 2003, Vol 30, Num 3, pp 34-46, issn 0093-7754, 13 p., SUP7Article

Integrin function in breast carcinoma progressionSHAW, L. M.Journal of mammary gland biology and neoplasia. 1999, Vol 4, Num 4, pp 367-376, issn 1083-3021Article

Optimal Targeting of HER2-PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical ImplicationsREXER, Brent N; ARTEAGA, Carlos L.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 13, pp 3817-3820, issn 0008-5472, 4 p.Article

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agentsROWINSKY, Eric K.Drugs (Basel). 2000, Vol 60, pp 1-14, issn 0012-6667, SUP1Article

The ErbB receptors as targets for breast cancer therapyALBANELL, J; BASELGA, J.Journal of mammary gland biology and neoplasia. 1999, Vol 4, Num 4, pp 337-351, issn 1083-3021Article

The epidermal growth factor receptor : From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasiaARTEAGA, Carlos L.Journal of clinical oncology. 2001, Vol 19, Num 18, pp 32s-40s, issn 0732-183X, SUPConference Paper

ZD1839 ('Iressa')^1,2 as an anticancer agentBASELGA, José; AVERBUCH, Steven D.Drugs (Basel). 2000, Vol 60, pp 33-40, issn 0012-6667, SUP1Article

Cdk inhibitor p27^kip1 and hormone dependence in breast cancerARTEAGA, Carlos L.Clinical cancer research. 2004, Vol 10, Num 1, pp 368s-371s, issn 1078-0432, 2Conference Paper

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapyRAYMOND, Eric; FAIVRE, Sandrine; ARMAND, Jean Pierre et al.Drugs (Basel). 2000, Vol 60, pp 15-23, issn 0012-6667, SUP1Article

Clinical Development of Phosphatidylinositol-3 Kinase Pathway InhibitorsARTEAGA, Carlos L.Current Topics in Microbiology and Immunology. 2010, Vol 347, pp 189-208, issn 0070-217X, 20 p.Article

Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancerARTEAGA, Carlos L; TRUICA, Cristina I.Seminars in oncology. 2004, Vol 31, Num 1, pp 3-8, issn 0093-7754, 6 p., SUP3Article